Mortality patterns in long-term survivors of childhood or adolescent central nervous system tumour in Sweden.
Central nervous system tumour
Long-term survivors
Mortality patterns
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
12
09
2019
accepted:
19
10
2019
pubmed:
5
11
2019
medline:
18
4
2020
entrez:
3
11
2019
Statut:
ppublish
Résumé
A growing number of young patients with central nervous system (CNS) tumour survived for more than five years. However, these long-term survivors might be at risk of multiple late effects thus leading to a higher risk of late mortality. We aimed to explore the risk of late mortality and the pattern of mortality among long-term survivors of childhood or adolescent CNS tumour. We identified 5-year survivors with childhood or adolescent CNS tumour before age 20 years through the Swedish Cancer Registry. Five controls were randomly matched for each patient to generate the reference group. We retrieved information about death via Cause of Death Register. We calculated the absolute excess risk (AER) of death and the hazard ratio (HR) of death using Cox proportional hazard model. Long-term survivors with CNS tumour suffered a significant higher risk of overall mortality (HR 6.56, 95% CI 5.71-7.53; AER 5.89, 95% CI 5.03-6.87). The mortality rate declined with the increasing survival time, but it was still higher even after 30 years of follow-up. Malignant neoplasms contributed mostly to late mortality with an AER of 3.75 (95% CI 2.95-4.75). Female survivors, survivors diagnosed at a younger age and survivors with medulloblastoma were particularly strongly associated with a higher risk of death. Long-term survivors of childhood and adolescent CNS tumours are at a higher risk of late mortality, and the risk of death is affected by gender, age at diagnosis and types of CNS tumour.
Identifiants
pubmed: 31677032
doi: 10.1007/s11060-019-03321-w
pii: 10.1007/s11060-019-03321-w
pmc: PMC6881431
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
541-549Subventions
Organisme : Svenska Forskningsrådet Formas
ID : 2016-02373
Organisme : Svenska Forskningsrådet Formas
ID : K2012-70X-15428-08-3
Organisme : Cancerfonden
ID : 2017 CAN2017/340
Organisme : Forskningsrådet för Arbetsliv och Socialvetenskap
ID : 2007-1754
Organisme : China Scholarship Council
ID : Grant No. 201806380121
Références
Radiat Res. 2010 Dec;174(6):741-52
pubmed: 21128798
Eur J Cancer. 2015 Nov;51(17):2665-77
pubmed: 26343313
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103
pubmed: 24488779
J Clin Oncol. 2009 May 10;27(14):2328-38
pubmed: 19332714
J Clin Oncol. 2008 Sep 20;26(27):4401-9
pubmed: 18802152
Int J Cancer. 2016 Jul 15;139(2):322-33
pubmed: 26950898
Eur J Cancer. 2013 Oct;49(15):3274-83
pubmed: 23756361
JAMA. 2010 Jul 14;304(2):172-9
pubmed: 20628130
BMJ. 2016 Sep 01;354:i4351
pubmed: 27586237
J Clin Endocrinol Metab. 2003 Feb;88(2):611-6
pubmed: 12574189
J Cancer Surviv. 2013 Sep;7(3):275-82
pubmed: 23471729
Int J Cancer. 2012 Nov 1;131(9):2085-93
pubmed: 22307919
Int J Cancer. 2012 Oct 1;131(7):1659-66
pubmed: 22170520
Cancer. 2003 Feb 1;97(3):663-73
pubmed: 12548609
Pediatr Blood Cancer. 2007 Apr;48(4):460-7
pubmed: 16767717
Nat Rev Endocrinol. 2016 Jun;12(6):319-36
pubmed: 27032982
J Child Neurol. 2016 Feb;31(2):237-54
pubmed: 26045296
Pediatr Blood Cancer. 2004 Jun;42(7):563-73
pubmed: 15127410
N Engl J Med. 2016 Mar 3;374(9):833-42
pubmed: 26761625